India business that includes branded formulations, trade generics and consumer health grew by 68% YoY to Rs 2,710 crore driven by volume growth in core therapies and support from existing and new introduction in covid portfolio through the second wave. In addition, acute and respiratory nebulization recovered well for the company.Cipla posts 24% YoY net profit growth in Q1FY22 led by core therapies, COVID portfolio
India business that includes branded formulations, trade generics and consumer health grew by 68% YoY to Rs 2,710 crore driven by volume growth in core therapies and support from existing and new introduction in covid portfolio through the second wave. In addition, acute and respiratory nebulization recovered well for the company.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment